Athira Pharma (ATHA) Stock Forecast, Price Target & Predictions
ATHA Stock Forecast
Athira Pharma stock forecast is as follows: an average price target of $18.00 (represents a 2712.94% upside from ATHA’s last price of $0.64) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
ATHA Price Target
The average price target for Athira Pharma (ATHA) is $18.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $33.00 to $3.00. This represents a potential 2712.94% upside from ATHA's last price of $0.64.
ATHA Analyst Ratings
According to 4 Wall Street analysts, Athira Pharma's rating consensus is 'Buy'. The analyst rating breakdown for ATHA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Athira Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 22, 2022 | Andrew Tsai | Jefferies | $3.00 | $2.85 | 5.26% | 368.82% |
| Apr 21, 2022 | - | Berenberg Bank | $33.00 | $11.63 | 183.75% | 5057.06% |
The latest Athira Pharma stock forecast, released on Jun 22, 2022 by Andrew Tsai from Jefferies, set a price target of $3.00, which represents a 5.26% increase from the stock price at the time of the forecast ($2.85), and a 368.82% increase from ATHA last price ($0.64).
Athira Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.64 | $0.64 | $0.64 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Athira Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Athira Pharma's last price of $0.64. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | Rodman & Renshaw | Buy | Neutral | Downgrade |
| Sep 04, 2024 | JMP Securities | Perform | Market Perform | Downgrade |
| Sep 04, 2024 | JMP Securities | Market Outperform | Perform | Downgrade |
| Sep 04, 2024 | BTIG | Neutral | Positive | Downgrade |
| Sep 03, 2024 | BTIG | - | Neutral | Downgrade |
| Aug 19, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Oct 17, 2022 | JMP Securities | - | Market Outperform | Upgrade |
| Jun 22, 2022 | Jefferies | - | Buy | Downgrade |
Athira Pharma's last stock rating was published by Rodman & Renshaw on Sep 04, 2024. The company Downgrade its ATHA rating from "Buy" to "Neutral".
Athira Pharma Financial Forecast
Athira Pharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $100.00K |
| High Forecast | - | - | - | - | - | - | - | $100.00K |
| Low Forecast | - | - | - | - | - | - | - | $100.00K |
| # Analysts | - | - | - | - | - | - | - | 1 |
| Surprise % | - | - | - | - | - | - | - | - |
Athira Pharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ATHA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Athira Pharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 |
| EBITDA | - | - | - | - | - | - | - | $-8.46M |
| Avg Forecast | - | - | - | - | - | - | - | $-17.44M |
| High Forecast | - | - | - | - | - | - | - | $-13.95M |
| Low Forecast | - | - | - | - | - | - | - | $-20.93M |
| Surprise % | - | - | - | - | - | - | - | 0.48% |
undefined analysts predict ATHA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Athira Pharma's previous annual EBITDA (undefined) of $NaN.
Athira Pharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 |
| Net Income | - | - | - | - | - | - | - | $-8.46M |
| Avg Forecast | $-14.20M | $-14.20M | $-15.35M | $-14.97M | $-19.70M | $-26.93M | $-28.29M | $-18.87M |
| High Forecast | $-14.20M | $-14.20M | $-15.35M | $-14.97M | $-19.70M | $-26.93M | $-28.29M | $-15.10M |
| Low Forecast | $-14.20M | $-14.20M | $-15.35M | $-14.97M | $-19.70M | $-26.93M | $-28.29M | $-22.65M |
| Surprise % | - | - | - | - | - | - | - | 0.45% |
Athira Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ATHA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Athira Pharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 |
| SG&A | - | - | - | - | - | - | - | $1.57M |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Athira Pharma's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ATHA last annual SG&A of $1.57M (Sep 20).
Athira Pharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 |
| EPS | - | - | - | - | - | - | - | $-1.12 |
| Avg Forecast | $-0.37 | $-0.37 | $-0.40 | $-0.39 | $-0.51 | $-0.70 | $-0.74 | $-0.25 |
| High Forecast | $-0.37 | $-0.37 | $-0.40 | $-0.39 | $-0.51 | $-0.70 | $-0.74 | $-0.25 |
| Low Forecast | $-0.37 | $-0.37 | $-0.40 | $-0.39 | $-0.51 | $-0.70 | $-0.74 | $-0.25 |
| Surprise % | - | - | - | - | - | - | - | 4.48% |
According to undefined Wall Street analysts, Athira Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ATHA previous annual EPS of $NaN (undefined).
Athira Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ATHA | Athira Pharma | $0.64 | $18.00 | 2712.50% | Buy |
| SPRO | Spero Therapeutics | $1.29 | $10.00 | 675.19% | Buy |
| CTMX | CytomX Therapeutics | $1.01 | $5.77 | 471.29% | Buy |
| NUVB | Nuvation Bio | $2.29 | $6.75 | 194.76% | Buy |
| TIL | Instil Bio | $27.63 | $78.25 | 183.21% | Hold |
| NXTC | NextCure | $1.31 | $3.00 | 129.01% | Buy |
| ASMB | Assembly Biosciences | $16.98 | $35.50 | 109.07% | Buy |
| ACHL | Achilles Therapeutics | $1.03 | $2.00 | 94.17% | Buy |
ATHA Forecast FAQ
Is Athira Pharma a good buy?
Yes, according to 4 Wall Street analysts, Athira Pharma (ATHA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 50.00% of ATHA's total ratings.
What is ATHA's price target?
Athira Pharma (ATHA) average price target is $18 with a range of $3 to $33, implying a 2712.94% from its last price of $0.64. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Athira Pharma stock go up soon?
According to Wall Street analysts' prediction for ATHA stock, the company can go up by 2712.94% (from the last price of $0.64 to the average price target of $18), up by 5057.06% based on the highest stock price target, and up by 368.82% based on the lowest stock price target.
Can Athira Pharma stock reach $1?
ATHA's average twelve months analyst stock price target of $18 supports the claim that Athira Pharma can reach $1 in the near future.
What are Athira Pharma's analysts' financial forecasts?
Athira Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-74.918M (high $-74.918M, low $-74.918M), average SG&A $0 (high $0, low $0), and average EPS is $-1.952 (high $-1.952, low $-1.952). ATHA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-58.721M (high $-58.721M, low $-58.721M), average SG&A $0 (high $0, low $0), and average EPS is $-1.53 (high $-1.53, low $-1.53).